« Back
Home /
Mouse Anti-Human VEGFR3/FLT4 Clone 1 mAb

Mouse Anti-Human VEGFR3/FLT4 Clone 1 mAb

Manufacturer	Cell Sciences
Category	Oncology Neuroscience Protein Aggregation, Clearance & Misfolding Antibodies By Cell Type Blastoma Carcinoma Hematology Leukemia Lymphoma Myeloma Melanoma Sarcoma Cell Biology Cell Movement Cell Adhesion Cell Culture Cytokines Adenocarcinoma Mesothelioma Western Blot ELISA Primary Antibodies By Organ Bladder Cancer Colorectal Cancer Heart & Blood Cancer
Type	Antibody Monoclonal
Specific against	Human
Clone	1
Isotype	IgG1
Applications	WB, ELISA
Amount	100 ug
Host	Mouse
Item no.	CS-CMV017
Targets	VEGFA, FLT4, ABL1, TTK, KDR
eClass 6.1	32160702
eClass 9.0	42030590
Available
Description	Mouse Anti-human VEGFR3/FLT4 Clone 1 monoclonal antibody. VEGFR3/FLT4, belongs to the class III subfamily of receptor tyrosine kinases. VEGFR3/FLT4 mediates the angiogenic activity of VEGFC and VEGFD on lymphatic endothelial cells.
Formulation	Lyophilized from PBS, pH 7.4 without preservative
Immunogen	Recombinant human soluble VEGFR3 protein
Purification	Protein G affinity chromatography
Reconstitution	Centrifuge vial prior to opening . Add sterile distilled water to the vial to fully solubilize the antibody to a concentration > 0.5 mg/ml.
Storage and Stability	Lyophilized antibody is stable for 1 month at 2-4C and for 1 year at -20C. Reconstituted antibody is stable for six weeks at 2-4C. Avoid repeated freeze-thaw cycles .
Specificity	Human VEGFR3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

CS-CMV017.pdf

CS-CMV017-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 100 ug

available

Delivery expected until 5/23/2024